IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of United Therapeutics Corporation and Encourages
Investors with Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces that it is investigating claims against United Therapeutics Corporation (“United
Therapeutics” or the “Company”) (Nasdaq: UTHR) concerning possible violations of federal securities laws.
If you purchased shares of United Therapeutics and want more information, please contact Joon M. Khang, Esquire, of Khang &
Khang LLP, 4000 Barranca Parkway, Suite 250 Irvine, CA 92604, by telephone: (949) 419-3834, or by
e-mail at joon@khanglaw.com.
The investigation concerns whether United Therapeutics and certain of its officers and/or directors violated federal securities
laws. On July 27, 2017, the Company revealed that it recorded a $210 million accrual relating to a potential settlement in
connection with a Department of Justice investigation into the Company’s possible violations of the Federal Anti-Kickback Statute
and the Federal False Claims Act. When this news was announced, shares of United Therapeutics fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost
two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006704/en/